(Q44116286)

29 November 2017

0 references

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis (English)

1 reference

29 November 2017

Gram-negative bacteria

0 references

1 reference

1

Nasia Safdar

1 reference

29 November 2017

2

Jo Handelsman

1 reference

29 November 2017

Dennis G Maki

3

1 reference

29 November 2017

1 August 2004

1 reference

Lancet Infectious Diseases

29 November 2017

1 reference

29 November 2017

4

1 reference

29 November 2017

8

1 reference

29 November 2017

519-527

1 reference

Risk factors for nosocomial infection in intensive care. 'Devices vs nature' and goals for the next decade

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antimicrobial-drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Enterobacter spp.: pathogens poised to flourish at the turn of the century

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Increasing threat of Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Impact of antibiotic resistance on clinical outcomes and the cost of care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Excess infections due to antimicrobial resistance: the "Attributable Fraction".

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Klebsiella pneumoniae bacteraemia at an urban general hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Multidrug-resistant Pathogens: Mechanisms of Resistance and Epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Monotherapy versus combination therapy for bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Combination Antimicrobial Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Meta-analysis in the design and monitoring of clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Gram-negative bacillary bacteremia in the elderly: incidence, ecology, etiology, and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Klebsiella bacteremia: an analysis of 100 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

1 reference

7 January 2021

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Pseudomonas aeruginosa bacteremia in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Retrospective analysis of clinical and microbiological aspects of Klebsiella oxytoca bacteremia over a 10-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antibiotics in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Development of resistance during antibiotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Synergistic combinations of antibiotics in gram-negative bacillary infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Synergy Between Ticarcillin and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae In Vitro and In Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

In Vitro Antibacterial Activity of Amikacin and Ticarcillin, Alone and in Combination, Against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Unpredictable Response of Pseudomonas aeruginosa to Synergistic Antibiotic Combinations In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

beta-Lactam resistance amongst Enterobacter species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Clinical importance of inducible beta-lactamases in gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901108-9

7 January 2021

10.1016/S1473-3099(04)01108-9

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

15288826